This article has been cited by other articles in PMC.
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (432K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
Von Hoff DD, Layard MW, Basa P, Davis HL, Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717.[PubMed]
Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer. 1974 Jan;33(1):19–27.[PubMed]
Brenner DE, Wiernik PH, Wesley M, Bachur NR. Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer. 1984 Mar 1;53(5):1042–1048.[PubMed]
Benjamin RS, Riggs CE, Jr, Bachur NR. Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):592–600.[PubMed]
Lee YT, Chan KK, Harris PA, Cohen JL. Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer. 1980 May 1;45(9):2231–2239.[PubMed]
Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press